Across TCGA pan-cancer cohorts, RAP1A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAP1A data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher RAP1A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAP1A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
SKCM, THCA, and CHOL are the cancer types where RAP1A Mutation most reproducibly stratifies survival.